The World Health Organization (WHO) response criteria for stable disease: A 50% decrease in total tumor size cannot be established, and a 25% increase in the size of one or more measurable lesions has not been demonstrated.2
Initiate 30 mg of Sandostatin® LAR® every 4 weeks for tumor control in patients with advanced midgut NET.3
67% (28/42) achieved stable disease at 6 months vs 37% (16/43) for placebo (N=85; P=0.0079).1
The recommended dose of Sandostatin® LAR® for tumor control in advanced midgut NET is 30 mg administered every 4 weeks. Treatment with Sandostatin® LAR® for tumor control should be continued in the absence of tumor progression.3
30 mg of Sandostatin® LAR®: The approved dose for tumor control.1
1. Rinke A, Muller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663. 2. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214. 3. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2018.